EUVIMEDFaigh amach EUVIMED
Open access · CC BY-NC-ND 4.0

Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients

Haoran Wei iD, Junfang Wu iD, Huiqing Wang, Jin Huang, Chenze Li, Yuxuan Zhang, Yaonan Song, Zhitong Zhou, Yang Sun, Lei Xiao, Liyuan Peng, Chen Chen iD and 2 more

Journal of Internal Medicine · 2023-10 · 294 (4) · 515-530

DOI: 10.1111/joim.13653 ↗

At a glance

Journal article in Journal of Internal Medicine, published online on 2023-05-30. Written by Haoran Wei and 13 co-authors. Institution: Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuha…. Major MEDLINE topics: Heart Failure. Cited 31 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

Background

Phenylacetylglutamine (PAGln)—a newly discovered microbial metabolite produced by phenylalanine metabolism—is reportedly associated with cardiovascular events via adrenergic receptors. Nonetheless, its association with cardiovascular outcomes in heart failure (HF) patients remains unknown.

Objectives

This study aimed to prospectively investigate the prognostic value of PAGln for HF.

Methods

Plasma PAGln levels were quantified by liquid chromatography‐tandem mass spectrometry. We first assessed the association between plasma PAGln levels and the incidence of adverse cardiovascular events in 3152 HF patients (including HF with preserved and reduced ejection fraction) over a median follow‐up period of 2 years. The primary endpoint was the composite of cardiovascular death or heart transplantation. We then assessed the prognostic role of PAGln in addition to the classic biomarker N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). The correlation between PAGln levels and β‐blocker use was also investigated.

Results

In total, 520 cardiovascular deaths or heart transplantations occurred in the HF cohort. Elevated PAGln levels were independently associated with a higher risk of the primary endpoint in a dose‐response manner, regardless of HF subtype. Concurrent assessment of PAGln and NT‐proBNP levels enhanced risk stratification among HF patients. PAGln further showed prognostic value at low NT‐proBNP levels. Additionally, the interaction effects between PAGln and β‐blocker use were not significant.

Conclusions

Plasma PAGln levels are an independent predictor of an increased risk of adverse cardiovascular events in HF. Our work could provide joint and complementary prognostic value to NT‐proBNP levels in HF patients.

Subjects

MeSH terms (MEDLINE)

Heart FailureHumansStroke VolumeBiomarkersPrognosisPeptide FragmentsNatriuretic Peptide, BrainGlutamine

Author keywords

NT-proBNPPAGlnbiomarkerheart failureβ-blocker

Substances

BiomarkersPeptide FragmentsNatriuretic Peptide, BrainphenylacetylglutamineGlutamine

Authors and institutions

  • Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
  • Department of Cardiology, Zhongnan Hospital of Wuhan University, Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China.

ORCID profiles: Haoran Wei, Junfang Wu, Chen Chen

Cite

APA

Wei, H., Wu, J., Wang, H., Huang, J., Li, C., Zhang, Y., Song, Y., Zhou, Z., Sun, Y., Xiao, L., Peng, L., Chen, C., Zhao, C., & Wang, D. W. (2023). Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients. Journal of Internal Medicine, 294(4), 515-530. https://doi.org/10.1111/joim.13653

Vancouver

Wei H, Wu J, Wang H, Huang J, Li C, Zhang Y, et al. Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients. Journal of Internal Medicine. 2023;294(4):515-530. doi:10.1111/joim.13653

BibTeX
@article{Wei2023,
  author = {Wei, Haoran and Wu, Junfang and Wang, Huiqing and Huang, Jin and Li, Chenze and Zhang, Yuxuan and Song, Yaonan and Zhou, Zhitong and Sun, Yang and Xiao, Lei and Peng, Liyuan and Chen, Chen and Zhao, Chunxia and Wang, Dao Wen},
  title = {Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {294},
  number = {4},
  pages = {515--530},
  doi = {10.1111/joim.13653}
}
Start for free →